insights_auto
Why is ALNY down 2,26%?
Dive Deeperchevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
227,43 USD
arrow_downward
-2,26%(-5,25) 1D
12-окт., 15:18:39 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
233,13 USD
High
233,60 USD
Low
227,07 USD
Mkt. cap
30,43 млд
Avg. vol.
1,49 млн
Volume
548,26 миң
P/E ratio
38,71
52-wk high
495,55 USD
52-wk low
197,81 USD
EPS
5,88 USD
Beta
0,28
Shares outstanding
133,81 млн
No. of employees
2 миң
Open
233,13 USD
High
233,60 USD
Low
227,07 USD
Mkt. cap
30,43 млд
Avg. vol.
1,49 млн
Volume
548,26 миң
P/E ratio
38,71
52-wk high
495,55 USD
52-wk low
197,81 USD
EPS
5,88 USD
Beta
0,28
Shares outstanding
133,81 млн
No. of employees
2 миң
News stories
From web sources and news partners
Stocks Down Under
·
38 мүнөт мурун
Alnylam Pharmaceuticals (NDQ:ALNY): This RNAi Pioneer Is Becoming A Cardiometabolic Heavyweight Right Before Our Eyes
Investing.com
·
1 күн мурун
Alnylam EVP Bryan Supran sells $398,855 in shares
Investing.com Nigeria
·
1 күн мурун
Form 4 Alnylam Pharmaceuticals Inc For: 11 October By Investing.com
Simply Wall Street
·
1 күн мурун
How Securities Fraud Scrutiny Will Impact Alnylam Stock Investors
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.